Agilon Health, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00857U1079
USD
0.70
0.03 (3.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

7.19 M

Shareholding (Mar 2025)

FII

8.52%

Held by 133 FIIs

DII

0

Held by 119 DIIs

Promoter

24.27%

How big is Agilon Health, Inc.?

22-Jun-2025

As of Jun 18, Agilon Health, Inc. has a market capitalization of 869.30 million, with net sales of 5,988.96 million and a net profit of -255.41 million over the latest four quarters.

As of Jun 18, Agilon Health, Inc. has a market capitalization of 869.30 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 5,988.96 million, while the sum of net profit for the same period is -255.41 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 470.95 million and total assets at 1,733.98 million.

Read More

What does Agilon Health, Inc. do?

22-Jun-2025

Agilon Health, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1.533 billion and a net profit loss of $2 million as of March 2025. Key metrics include a market cap of $869.30 million, a negative P/E ratio, and a dividend yield of 0.00%.

Overview: <BR>Agilon Health, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,533 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 869.30 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.67 <BR>Return on Equity: -49.80% <BR>Price to Book: 1.74<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Agilon Health, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Agilon Health, Inc. is in a bearish trend with significant underperformance, showing a year-to-date return of -38.42% compared to the S&P 500's 12.22%.

As of 9 September 2025, the technical trend for Agilon Health, Inc. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. The Bollinger Bands are showing a mildly bearish trend on the weekly and a bearish trend on the monthly. The KST is bearish on the weekly and mildly bullish on the monthly, while the Dow Theory shows no trend in both weekly and monthly time frames. <BR><BR>In terms of performance, Agilon Health has significantly underperformed compared to the S&P 500, with a year-to-date return of -38.42% versus the S&P 500's 12.22%, and a one-year return of -70.68% compared to 17.14% for the index. Overall, the current technical stance is bearish, indicating weakness in the stock's performance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Negative results in Jun 25

  • PRE-TAX PROFIT(Q) At USD -104.19 MM has Fallen at -68.49%
  • NET PROFIT(Q) At USD -104.25 MM has Fallen at -67.37%
  • ROCE(HY) Lowest at -60.64%
2

Risky - Negative EBITDA

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 522 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.71

stock-summary
Return on Equity

-79.13%

stock-summary
Price to Book

1.28

Revenue and Profits:
Net Sales:
1,395 Million
(Quarterly Results - Jun 2025)
Net Profit:
-104 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.27%
0%
-40.27%
6 Months
-67.94%
0%
-67.94%
1 Year
-64.16%
0%
-64.16%
2 Years
-94.57%
0%
-94.57%
3 Years
-95.94%
0%
-95.94%
4 Years
-97.0%
0%
-97.0%
5 Years
0%
0%
0.0%

Agilon Health, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
39.78%
EBIT Growth (5y)
2.55%
EBIT to Interest (avg)
-41.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.07
Sales to Capital Employed (avg)
7.79
Tax Ratio
0.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.79
EV to EBIT
-1.86
EV to EBITDA
-2.04
EV to Capital Employed
3.37
EV to Sales
0.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-180.74%
ROE (Latest)
-49.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 59 Schemes (74.44%)

Foreign Institutions

Held by 133 Foreign Institutions (8.52%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -8.99% vs 0.68% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -5,394.74% vs 98.21% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,395.00",
          "val2": "1,532.80",
          "chgp": "-8.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-108.60",
          "val2": "-14.70",
          "chgp": "-638.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "1.50",
          "chgp": "6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.50",
          "chgp": "80.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-104.40",
          "val2": "-1.90",
          "chgp": "-5,394.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-83.10%",
          "val2": "-14.10%",
          "chgp": "-6.90%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 40.41% vs 80.74% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -28.16% vs -111.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,060.50",
          "val2": "4,316.40",
          "chgp": "40.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-259.50",
          "val2": "-211.80",
          "chgp": "-22.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.20",
          "val2": "6.70",
          "chgp": "-7.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.20",
          "val2": "-0.20",
          "chgp": "-4,000.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-250.30",
          "val2": "-195.30",
          "chgp": "-28.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-46.90%",
          "val2": "-53.70%",
          "chgp": "0.68%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1,395.00
1,532.80
-8.99%
Operating Profit (PBDIT) excl Other Income
-108.60
-14.70
-638.78%
Interest
1.60
1.50
6.67%
Exceptional Items
-0.10
-0.50
80.00%
Consolidate Net Profit
-104.40
-1.90
-5,394.74%
Operating Profit Margin (Excl OI)
-83.10%
-14.10%
-6.90%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -8.99% vs 0.68% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -5,394.74% vs 98.21% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
6,060.50
4,316.40
40.41%
Operating Profit (PBDIT) excl Other Income
-259.50
-211.80
-22.52%
Interest
6.20
6.70
-7.46%
Exceptional Items
-8.20
-0.20
-4,000.00%
Consolidate Net Profit
-250.30
-195.30
-28.16%
Operating Profit Margin (Excl OI)
-46.90%
-53.70%
0.68%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 40.41% vs 80.74% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -28.16% vs -111.59% in Dec 2023

stock-summaryCompany CV
About Agilon Health, Inc. stock-summary
stock-summary
Agilon Health, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available